Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

84
Tracking Dan Loeb's Third Point Portfolio - Q2 2018 Update

2018-08-12 seekingalpha
Dan Loeb's 13F portfolio value increased from $13.32B to $14.35B this quarter. The number of positions decreased from 40 to 38.
ATHTF STZ.B TWX CRM DOW DOV MELI PBF TPRE WP KDMN STZ UTX BKI TWC PVH DVMT FPAC.U GOOGL MSFT APY MHK TPNTF GRBK FB DOV.WI LEN NXPI PYPL NFLX BAX GOOG LEN.B MPC PAGS ADBE SPGI EGN MON ICE SHY CWH EA WYNN ANTM DWDP BID BLK V DHR ANTX

43
Forget Amazon, GM's Move Should Worry Health Insurers - Bloomberg

2018-08-07 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
ATHTF BRK.A ANTM GM CI UNH DIS ANTX

9
Carl Icahn Knows It's Never Too Late to Derail a Deal - Bloomberg

2018-08-07 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
ATHTF BRK.A ANTM CI ANTX

15
Zacks.com highlights: Intel, Kroger, Progressive, Anthem and Matson

2018-08-06 zacks
Chicago, IL – August 6, 2018 - Stocks in this week’s article include: Intel (INTC - Free Report) , The Kroger Co. (KR - Free Report) , The Progressive Corp. (PGR - Free Report) , Anthem Inc. (ANTM - Free Report) and Matson Inc. (MATX - Free Report) .
ATHTF PGR ANTM MATX GIII BGSF ADBE ECHO RCKY KR MTN VNDA MLNX ARW CVLT ADM INTC HUBG HUBOF ANTX

115
Tracking Yacktman Asset Management Portfolio - Q2 2018 Update

2018-08-06 seekingalpha
Yacktman Asset Management decreased Twenty-First Century Fox, Microsoft, Sysco, and Cisco Systems substantially during the quarter.
ATHTF SYY XOM ULVR AVP RDI CHRW UNLNF UHAL SYK CSCO CMCSK ABBV HSY MO CRMT FOX GLW BAC HSYFB NWS NWSA UNLYF INFY BRK.A JNJ BK INFY ABBV MSFT CLX FOXA WFCNP PG CCV CCZ BAC COP OTEL PM RDIB NWS KO ORCL DIS WFC GJV UL UN CMCSA ANTM PEP CCV.CL OCLCF ANTX

7
Humana (HUM) Surpasses on Q2 Earnings, Raises EPS Guidance

2018-08-01 zacks
Humana Inc.’s (HUM - Free Report) second-quarter 2018 operating earnings per share of $3.96 beat the Zacks Consensus Estimate of $3.21. The bottom line also improved 13.4% year over year.
ATHTF BRK.A CNC ANTM HUM UNH ANTX

6
WellCare Health (WCG) Beats on Q2 Earnings, Updates Guidance

2018-08-01 zacks
WellCare Health Plans, Inc. (WCG - Free Report) delivered second-quarter 2018 adjusted operating earnings of $3.69 per share, beating the Zacks Consensus Estimate of $3.03 by 21.8%. The bottom line also surged 46.4% year over year.
ATHTF BRK.A UAM CNC WCG ANTM UNH ANTX UAMCP

7
Acadia Healthcare (ACHC) Posts In-Line Q2 Earnings, Cuts View

2018-07-31 zacks
Acadia Healthcare Company, Inc. (ACHC - Free Report) reported second-quarter 2018 adjusted earnings of 70 cents per share, which remains in line with the Zacks Consensus Estimate. Meanwhile, the bottom line improved 6.1% year over year.
ATHTF FCN UHID ACHC SFUN ANTM UTX UHS ANTX

0
Castlight Health, Inc. (CSLT) CEO John Doyle on Q2 2018 Results - Earnings Call Transcript

2018-07-31 seekingalpha
Good afternoon. My name is Mike and I will be your conference operator today. At this time, I would like to welcome everyone to the Castlight Health Q2 2018 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions]
ATHTF CSLT ANTM ANTX

3
Universal Health (UHS) Q2 Earnings Beat Estimates, Up Y/Y

2018-07-26 zacks
Universal Health Services Inc. (UHS - Free Report) reported second-quarter 2018 adjusted earnings of $2.47 per share, beating the Zacks Consensus Estimate by 3.3%. Moreover, the bottom line improved 27.3% year over year.
ATHTF CNC UHID ANTM UHS UNH ANTX

21
RPT-FOCUS-Amgen's new migraine drug hits insurance hurdles

2018-07-26 reuters
July 26 (Reuters) - Amgen Inc’s push to get patients on its new $575 a month migraine drug before competition emerges in September is facing barriers from insurers.
ATHTF PFZ AMGN TEVA TEVVF ANTM ACT PFIZER TEVJF AGN NVS 500680 AET UNH PFE ALDR ANTX

21
FOCUS-Amgen's new migraine drug hits insurance hurdles

2018-07-26 reuters
(Reuters) - Amgen Inc’s push to get patients on its new $575 a month migraine drug before competition emerges in September is facing barriers from insurers.
ATHTF PFZ AMGN TEVA TEVVF ANTM ACT PFIZER TEVJF AGN NVS 500680 AET UNH PFE ALDR ANTX

21
Amgen's new migraine drug hits insurance hurdles - Channel NewsAsia

2018-07-26 channelnewsasia
REUTERS: Amgen Inc's push to get patients on its new US$575 a month migraine drug before competition emerges in September is facing barriers from insurers.
ATHTF PFZ AMGN TEVA TEVVF ANTM ACT PFIZER TEVJF AGN NVS 500680 AET UNH PFE ALDR ANTX

6
HCA Healthcare (HCA) Beats on Q2 Earnings, Revises Guidance

2018-07-25 zacks
HCA Healthcare, Inc. (HCA - Free Report) reported second-quarter 2018 adjusted earnings of $2.29 per share, surpassing the Zacks Consensus Estimate of $2.14 by 7%. Moreover, the bottom line shot up nearly 32% year over year.
ATHTF LMT CNC BP DTJ ANTM BP.A BP.B BP DTW DTV BPAQF DTY UNH ANTX

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

CUSIP: 036752202